B
BVF Partners L.P.
+ HoldingNCEL
+11.78%
3M Return
$3.190
-0.215 (-6.73%)收盤時
Loading chart…
- High
- 3.370
- Open
- 3.370
- VWAP
- 3.25
- Vol
- 12.44K
- Mkt Cap
- —
- Low
- 3.190
- Amount
- 40.41K
- EV/EBITDA, TTM
- 0.00
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
AI analysis of NewcelX AG (NCEL)
buyNewcelX AG (NCEL) appears to be a good buy right now due to its recent private placement at a 30% premium to the last closing price, which reflects strong market confidence. The current price is $3.19, and the stock has shown a year-to-date change of +52.63%, indicating positive momentum despite a one-year change of -95.81%. However, the main risk is the negative P/E ratio of -4.71, suggesting ongoing financial challenges.
估值指標
The current forward P/E ratio for NewcelX AG (NCEL) is 0.00, compared to its 5-year average forward P/E of 0.00.
Whales holding NCEL
事件時間軸
資訊
8.507-31NewsfilterNewcelX Secures Private Placement to Advance Diabetes Therapy
- 5.007-08Newsfilter
NewcelX Appoints Diabetes Research Authority Dr. Camillo Ricordi to Advisory Board
- 8.507-08Newsfilter
Avaí Bio Completes GMP Master Cell Bank for Anti-Aging Therapy
- 8.507-01Newsfilter
NewcelX Completes Successful FDA Meeting, Advancing Diabetes Treatment
- 3.506-15Newsfilter
NewcelX Publishes AstroRx® Study Results
NCEL FAQ — answered by Alphio AI
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ. It operates in the Healthcare sector.
NewcelX AG (NCEL) appears to be a good buy right now due to its recent private placement at a 30% premium to the last closing price, which reflects strong market confidence. The current price is $3.19, and the stock has shown a year-to-date change of +52.63%, indicating positive momentum despite a one-year change of -95.81%. However, the main risk is the negative P/E ratio of -4.71, suggesting ongoing financial challenges.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。